CONNECTA Therapeutics — Grant · €2.7M

A public-private consortium formed by CONNECTA Therapeutics, the CRG, the Hospital del Mar Research Institute and I3PT was awarded €2.7 million by Spain's Ministry of Science, Innovation and Universities under the EU Next Generation programme to start Phase IIa trials of CTH120 for Fragile X syndrome. This is a competitive public grant rather than an equity round; CONNECTA's private backers are Prous Institute for Biomedical Research, Inveready and CDTI Innvierte.

Lead unknown RoundGrant Announced12 Feb 2024Not counted in totals CityBarcelona SectorBiotechSource

Something wrong? Suggest a correction →

The company

Investors 2

European Union – Next Generation EU
European Union
Ministerio de Ciencia, Innovación y Universidades
Spain

← All funding rounds

Start typing to search across everything.
↑↓ navigate↵ openesc close? shortcuts
Keyboard shortcuts
/ Ctrl K
Search
j k
Next or previous row
↵
Open the row
Ctrl ↵
Open it in a new tab
[ ]
Previous or next page
?
This list